# Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

> **NCT02927431** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 10 (actual)

## Conditions studied

- Virus Diseases

## Interventions

- **DRUG:** Danirixin 15 mg FBE
- **DRUG:** Danirixin 50 mg FBE
- **DRUG:** Placebo
- **DRUG:** Oseltamivir 75 mg

## Key facts

- **NCT ID:** NCT02927431
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-19
- **Primary completion:** 2017-05-24
- **Final completion:** 2017-05-24
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The study was stopped early due to lack of enrollment.
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02927431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02927431, "Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02927431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*